日本における MBDD の現状の問題点と今後の課題

笠井 英史

doi:10.5691/jjb.32.s195

書誌事項

タイトル別名

Current and Future of Model-Based Drug Development in Japan

説明

Model-Based drug development (MBDD) is not so widely used Japan relative to U. S. A and EU. This is because 1) not so many well educated pharmacometricians with enough skills exist in Japan, 2) necessary databases for MBDD are not well organized in Japan. These two deficiencies lead to the paucity of disease progression model for Japanese patients. Pharmacometricians including pahramacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.

収録刊行物

計量生物学

計量生物学 32 (Special_Issue_2), S195-S196, 2011

日本計量生物学会

キーワード

詳細情報詳細情報について

CRID: 1390001204369106944

NII論文ID: 130002151414

DOI: 10.5691/jjb.32.s195

ISSN: 21856494; 09184430

本文言語コード: ja

データソース種別

JaLC
Crossref
CiNii Articles

抄録ライセンスフラグ: 使用不可

書き出し

問題の指摘